menu
    • menu
    [{"orgOrder":0,"company":"Lucis Pharma","sponsor":"Rosemont","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Alimemazine","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Lucis Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lucis Pharma \/ Rosemont","highestDevelopmentStatusID":"12","companyTruncated":"Lucis Pharma \/ Rosemont"}]

    Find Clinical Drug Pipeline Developments & Deals for Alimemazine

    Menu

    Alimemazine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lucis Pharma

                            United Kingdom arrow
                            BioFlorida Conference
                            Not Confirmed

                            Lucis Pharma

                            United Kingdom arrow
                            BioFlorida Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alimemazine

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Rosemont

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Rosemont Expands its Offering with Portfolio Acquisition from Lucis Pharma Ltd

                            Details : Through the acquisition, Rosemont will expand its existing portfolio and have access to a pipeline of innovative products including, alimemazine tartrate, an oral solution, used for the management of urticaria and pruritus.

                            Brand Name : Alimemazine Tartrate-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 16, 2023

                            Lead Product(s) : Alimemazine

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Rosemont

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth